Sign in
TerminatedPhase 1

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Key facts

Who runs it
Joseph Jurcic
Where
New York, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
2 people enrolled
Started
28 Jan 2022
Ended
9 Apr 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Fedratinib Oral Capsule 300 mg
  • Decitabine 20 mg/m2
  • Fedratinib Oral Capsule 400 mg
Record updated
23 April 2024
Why it stopped
Closed by Sponsor

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Subjects must have MPN-AP as defined by 10%-19% blasts in the peripheral blood or bone marrow and evidence of dysplastic marrow features with a concomitant diagnosis of essential thrombocythemia (ET), polycythemia vera (PV) or primary myelofibrosis (PMF) or a diagnosis of MPN-BP as defined by 20% blasts in the blood or bone marrow following a previous diagnosis of ET, PV or PMF
  • Subjects must have adequate organ function documented within 14 days of study entry as follows:; Estimated creatinine clearance (by Cockcroft-Gault Equation) of ≥ 50 mL/min; Serum total bilirubin ≤ 1.5 × ULN (unless attributable to Gilbert's disease or hemolysis, in which case the direct bilirubin level must be ≤ 1.5 × upper limit of normal (ULN)); Alkaline phosphatase, serum aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN
  • ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2. Patients with ECOG performance status of 3 will be eligible if the lower performance status is deemed by the investigator to be due entirely to MPN-AP/BP and not due to another comorbidity

Who cannot take part

  • Receipt of chemotherapy or investigational therapy, with the exception of hydroxyurea, within 4 weeks of study entry. Previous treatment at any time with decitabine, fedratinib or ruxolitinib as single agents will not exclude eligibility. Previous stem cell transplant will not exclude eligibility as long as other inclusion/exclusion criteria have been met and subjects do not have Grade ≥ II graft-versus-host disease (GVHD) requiring systemic immunosuppressive therapy
  • Subjects who are receiving any concurrent treatment for acute myeloid leukemia (AML), including other investigational agents
  • Uncontrolled intercurrent illness including, but not limited to hepatitis, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class 3 or 4), unstable angina pectoris, ventricular arrhythmia, Child-Pugh Class C cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements
  • Subjects with a prior history of Wernicke's encephalopathy (WE) will be excluded. If a subject has signs or symptoms of encephalopathy, including Wernicke's encephalopathy (e.g. severe ataxia, ocular paralysis or cerebellar signs), thiamine deficiency must be excluded and a brain MRI should be obtained prior to study initiation to evaluate for WE
  • Subjects with an Human leukocyte antigen (HLA)-compatible donor or stem cell source who are immediate candidates for allogeneic hematopoietic cell transplantation (HCT)
  • Other medications, severe acute/chronic medical or psychiatric conditions, or laboratory abnormalities that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, that in the judgment of the Investigator would make the subject inappropriate for entry into this study
  • Diagnosis of acute myelofibrosis
  • Pregnant women are excluded because of the potential for teratogenic or abortifacient effects

Where in United States

  • New York Presbyterian Hospital/Columbia University Irving Medical CenterNew York, United States

About the trial

What the trial wants to find out

The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs.

The 2 groups in the trial

  • Fedratinib 300 mgTreatment being tested

    Cohort 1: 300 mg of Fedratinib by mouth, once daily during each 28-day cycle

    Treatment: Fedratinib Oral Capsule 300 mg and Decitabine 20 mg/m2

  • Fedratinib 400 mgTreatment being tested

    Cohort 2: 400 mg of Fedratinib by mouth, once daily during each 28-day cycle

    Treatment: Decitabine 20 mg/m2 and Fedratinib Oral Capsule 400 mg

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I Trial of Fedratinib in Combination With Decitabine in Patients With Myeloproliferative Neoplasms in Accelerated and Blast Phase
Record updated
23 April 2024